Actinium Says DMC Recommends Phase 3 SIERRA Trial Continue To Full Enrolment Of 150 Patients

Actinium Pharmaceuticals, Inc. (ATNM) said Tuesday that the independent Data Monitoring Committee or DMC has completed the single ad hoc interim analysis of the pivotal Phase 3 SIERRA study of Iomab-B for bone marrow transplant (BMT) conditioning in patients aged above 55 with active relapsed or refractory Acute Myeloid Leukemia...

Read Full Story

If the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com

Actinium BMT DMC Data Monitoring Committee Iomab-B SIERRA